The growing inclination for biologics and biosimilars is driving the sterile injectable contract manufacturing market.New ...

The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...

On Wednesday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $61 which represents a slight increase of $0.25 or 0.41% from the prior close of $60.75. The stock opened at $60.95 and ...

Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.

Charles Schwab Investment Management Inc. boosted its stake in Catalent, Inc. (NYSE:CTLT – Free Report) by 1.1% during the ...

Update 12:35pm: Adds Reuters report. Catalent (NYSE:CTLT) rose 2.2% amid reports that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings ...

Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

Contract manufacturing revenues in the pharmaceutical finished dose sector witnessed a significant slowdown over the past ...